A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 613 participants.
Also called NCT04492722
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 613 participants
- Sponsor
- Registry
-
NCT04492722 -
2020-002263-54
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Brazil, Germany, Hungary, Israel, Japan, Malaysia, Poland, Taiwan, Ukraine
- Registry status
- Terminated
Technical summary
Registry record NCT04492722. Randomized; quadruple masking; primary purpose treatment. Start 2020-10-01 (actual); primary completion 2022-09-06 (actual). Results posted on 2023-12-26.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- AZD5718
- Intervention (Drug)
- Dapagliflozin 10 mg
- Intervention (Drug)
- Placebo
- Lead sponsor
- AstraZeneca
- Collaborator
- Parexel
- Collaborator
- Emerald Clinical Inc.
Record details
- Record id
cardio:ct-nct04492722- Content hash
3182bcb2d3ddf0106b4a22071d6094122fcda2b399c8222129d15c57173c58a8